SanegeneBio Initiates Phase 2 Trial of an Experimental RNAi-Based Medicine SGB-9768 Targeting C3 mRNA
Mar 7, 2025
— Phase 2 study evaluates efficacy and safety in complement-mediated kidney diseases —
BOSTON, SHANGHAI, and SUZHOU – March 7, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced the initiation of a Phase II clinical trial in China for SGB-9768, its investigational siRNA targeting complement component 3 (C3). The trial is being led by Peking University First Hospital and will enroll patients across multiple centers.
SGB-9768 is the first RNAi medicine targeting C3 to enter Phase 2 in China, reinforcing SanegeneBio's leadership in complement-targeted RNAi drug development. The multicenter, open-label study will evaluate efficacy and safety in patients with IgA nephropathy (IgAN), C3 glomerulopathy (C3G), and IC-MPGN.
Developed using SanegeneBio's proprietary GalNAc platform, SGB-9768 delivers RNAi specifically to hepatocytes to suppress C3 expression, thereby downregulating complement activation. Preclinical and Phase I data presented at the 2024 Complement-Based Drug Development Summit demonstrated:
Robust, dose-dependent, and sustained reduction in C3 levels following a single subcutaneous dose
Superior knockdown potency and durability compared to benchmark siRNAs
Favorable safety and tolerability profile
said Dr. Weimin Wang, Founder and CEO of SanegeneBio.
About Complement-Mediated Kidney Diseases
The complement system is a key part of innate immunity. Dysregulation of the C3-dependent pathway contributes to kidney and systemic diseases including IgAN, C3G, and IC-MPGN. Targeting C3 offers a strategic point of intervention to broadly modulate complement activity upstream, addressing a significant unmet medical need in chronic kidney disease (CKD), which affects over 10% of adults in China.
About SGB-9768
SGB-9768 is a GalNAc-conjugated experimental RNAi-based medicine designed to silence C3 mRNA in liver cells. It has demonstrated potent, sustained C3 suppression in preclinical models, with the potential for infrequent dosing and long-term efficacy. With a favorable safety profile and greater durability than comparator molecules, SGB-9768 may become a best-in-class RNAi therapeutic for complement-mediated diseases.
About SanegeneBio
SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021, SanegeneBio is led by a team of RNAi pioneers with unrivaled experience in this Nobel Prize-winning technology. With R&D operations in Boston, Shanghai and Suzhou, our vision clear – RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for countless patients in the coming years. Our fast-growing pipeline includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for several experimental medicines, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage with us on LinkedIn.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. Any statements in this release other than statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "could," "potential," "is/are likely to," "will," "plan," "intend," "aim," "expect," "anticipate," "believe," "hope," "estimate," "project," "forecast," "continue," "target," and similar expressions (or the negative of these terms) are intended to identify forward-looking statements. In addition, statements that refer to future results, trends in our business, expectations for our product pipeline or product candidates, or other characterizations of future events or circumstances are forward-looking statements.
These forward-looking statements are based on our current expectations and assumptions as of the date of this news release and speak only as of such date. They are not guarantees of future performance, and actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of risks and uncertainties, many of which are beyond our control. These risks and uncertainties include, without limitation: risks in research and development and clinical trials; regulatory review, requirements, and timing; trial initiation, site activation, enrollment, and operational execution (including performance by third parties); manufacturing, supply, and quality risks; the impact of competition and new technologies; future market conditions; macroeconomic, political, legal, and social conditions; and our ability to obtain and maintain sufficient funding and other resources. Readers are cautioned not to place undue reliance on these forward-looking statements. We assume no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by applicable law.
Medical Information
This press release is provided for informational purposes only and is intended to share scientific and disease-related information. It is not intended as advertising or commercial promotion of any product and does not constitute medical advice, a diagnosis, or a recommendation for any treatment or use of any product. For questions about medical conditions or treatment, please seek advice from a healthcare professional.